Therapies Development Targeting Type IV Secretion Systems of A. Baumannii

At Ace Therapeutics, we recognize the critical need for developing potent therapies to combat the menace of superbugs, like A. baumannii. One of the critical factors that contribute to the virulence of A. baumannii is its Type IV Secretion Systems (T4SSs). These intricate molecular machines enable the bacterium to transmit DNA and proteins to other cells, including genes that confer resistance to antibiotics. By targeting T4SSs, we can potentially prevent the spread of antibiotic resistance and improve treatment options for A. baumannii infections.

T4SSs of A. Baumannii

A. baumannii has multiple types of T4SSs, which are classified by their genetic makeup and function.

The most well-studied T4SS in A. baumannii is the conjugative pili T4SS, which facilitates the transfer of plasmids and other mobile genetic elements between bacterial cells. This particular T4SS has been linked to the dissemination of antibiotic resistance genes and the emergence of multidrug-resistant strains of A. baumannii.

Additionally, A. baumannii possesses another T4SS, the ComB T4SS, which plays a crucial role in natural transformation. This process involves the uptake of DNA from the environment and has been found to be essential for the acquisition of antibiotic resistance genes in A. baumannii.

Our Development Services

Our team of experienced scientists uses cutting-edge technologies and approaches to identify and develop novel therapies that target these important virulence factors.

We begin by consulting with our clients to understand their research goals and objectives. Then we develop a customized plan that outlines the services we will provide according their specific needs. And we offer a comprehensive service and use a range of technologies to collaborate with our clients to design and execute target identification, drug design, preclinical trials, and evaluate the safety and efficacy of our therapies in models of A. baumannii infection.

Several Strategies Targeting A. Baumannii's T4SSs

Inhibiting the assembly of T4SS components

We can design small molecule compounds to target specific components of T4SSs, inhibiting their assembly and preventing their function.

Blocking the secretion of effector molecules

We can develop small molecule compounds or biologics to block the secretion of these molecules, preventing their transfer to other cells.

Disrupting the function of T4SSs

We can develop small molecule compounds or biologics to disrupt the function of T4SSs, preventing the transfer of DNA and proteins between cells.

Our Service Process

At our company, we make sure that our clients receive top-notch services and accomplish their research objectives by following a well-designed service process. We collaborate closely with our clients to comprehend their unique needs and create tailored solutions that fulfill their requirements.

Our service process for therapies development targeting type IV secretion systems of A. baumannii. – Ace TherapeuticsFig. 1 Our service process for therapies development targeting type IV secretion systems of A. baumannii.

Ace Therapeutics is dedicated to creating effective therapies that target T4SSs of A. baumannii. We encourage you to contact us to gain more insights into how we can help you develop therapies that specifically target T4SSs of A. baumannii.


  1. Eijkelkamp B A, et al. Comparative analysis of surface-exposed virulence factors of Acinetobacter baumannii. BMC Genomics, 2014; 15:1020.
  2. Harding C M, et al. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol, 2018; 16(2):91-102.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Get in touch with our team immediately.